GleamWall
中文EN

BOLT Bolt Biotherapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1641281 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-51.3%
TTM net income YoY38.7%
TTM EPS YoY37.1%
Revenue 3-yr CAGR-29.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,098.0%
Net margin-1,034.4%
FCF margin—
EBITDA margin-1,068.0%

Returns

ROE-128.8%
ROA-52.0%
ROIC (approx.)-481.0%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets75.9%
Debt / equity0.00x
Current ratio2.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-2.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$7.70M$7.69M
R&D expense$28.53M$57.47M
SG&A expense$13.79M$18.46M
Operating income-$36.11M-$73.05M
Pretax income-$33.38M-$63.12M
Income tax$0$0
Net income-$33.38M-$63.12M
EBITDA-$34.82M-$71.27M
EPS (basic)-17.85-33.06
EPS (diluted)-17.85-33.06
Weighted avg. shares (diluted)1.87M1.91M
Balance sheet
Cash & equivalents$11.70M$7.21M
Short-term investments$15.80M$40.12M
Current assets$30.26M$50.81M
PP&E, net$1.25M$3.14M
Total assets$56.75M$99.63M
Current liabilities$8.44M$15.86M
Total liabilities$30.24M$42.43M
Shareholders' equity$26.50M$57.20M
Shares outstanding1.92M1.92M
Cash flow statement
Operating cash flow-$39.85M-$61.29M
Capital expenditure$72,000$41,000
Free cash flow-$39.92M-$61.33M
Investing cash flow$44.30M$57.58M
Financing cash flow$19,000$108,000
Depreciation & amortization$1.29M$1.78M
Stock-based compensation$2.78M$7.41M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.